SCHEMBL256335

SCHEMBL256335

CC1=NCN=C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2666331 0.75
SCHEMBL12922727 0.65
SCHEMBL11956821 0.65
SCHEMBL10296458 0.61
SCHEMBL14237646 0.59
SCHEMBL9926415 0.58
SCHEMBL11891519 0.55
SCHEMBL824748 0.52
SCHEMBL7703054 0.52
SCHEMBL791698 0.52

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050171028-A1 Thioketals and thioethers for inhibiting the expression of VCAM-1 ATHEROGENICS PHARMACEUTICALS, INC. 2005-08-04 US claimed
EP-1289944-A2 THIOKETALS AND THIOETHERS FOR INHIBITING THE EXPRESSION OF VCAM-1 Atherogenics, Inc. (US) 2003-03-12 EP claimed
US-20020016300-A1 Thioketals and thioethers for inhibiting the expression of VCAM-1 CRABTREE ACQUISITION CO, LLC 2002-02-07 US claimed
WO-2001070757-A2 THIOKETALS AND THIOETHERS FOR INHIBITING THE EXPRESSION OF VCAM-1 ATHEROGENICS, INC. (US) 2001-09-27 WO claimed
EP-3143026-B1 COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS NOVARTIS AG (CH) 2024-07-10 EP disclosed
US-11840521-B2 Modulators of Mas-related G-protein receptor X4 and related products and methods ESCIENT PHARMACEUTICALS, INC. (US) 2023-12-12 US disclosed
US-20230159474-A1 MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS INCYTE CORPORATION 2023-05-25 US disclosed
US-11643399-B2 Modulators of mas-related G-protein receptor X4 and related products and methods ESCIENT PHARMACEUTICALS, INC. (US) 2023-05-09 US disclosed
WO-2022078356-A1 HETEROAROMATIC AHR INHIBITOR 山东轩竹医药科技有限公司 2022-04-21 WO disclosed
WO-2021126995-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER ENGINE BIOSCIENCES PTE. LTD. (SG) 2021-06-24 WO disclosed
EP-3786290-A1 PEPTIDES AND METHODS FOR THE CARBON-CARBON BOND FORMATION Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2021-03-03 EP disclosed
WO-2020120994-A1 OREXIN 1 RECEPTOR ANTAGONISTS HEPTARES THERAPEUTICS LIMITED (GB) 2020-06-18 WO disclosed
US-20070191312-A1 NOVEL HETEROCYCLIC COMPOUNDS, PREPARATION PROCESS AND INTERMEDIATES, AND USE AS MEDICAMENTS, IN PARTICULAR AS BETA-LACTAMASE INHIBITORS AND ANTIBACTERIALS MUSICKI BRANISLAV 2007-08-16 US disclosed
US-20070049495-A1 Ethylene derivatives and pesticides containing said derivatives NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2007-03-01 US disclosed
US-20050171028-A1 Thioketals and thioethers for inhibiting the expression of VCAM-1 ATHEROGENICS PHARMACEUTICALS, INC. 2005-08-04 US disclosed
US-6852878-B2 Thioketals and thioethers for inhibiting the expression of VCAM-1 ATHEROGENICS, INC. (US) 2005-02-08 US disclosed
EP-1289944-A2 THIOKETALS AND THIOETHERS FOR INHIBITING THE EXPRESSION OF VCAM-1 Atherogenics, Inc. (US) 2003-03-12 EP disclosed
US-20020016300-A1 Thioketals and thioethers for inhibiting the expression of VCAM-1 CRABTREE ACQUISITION CO, LLC 2002-02-07 US disclosed
WO-2001070757-A2 THIOKETALS AND THIOETHERS FOR INHIBITING THE EXPRESSION OF VCAM-1 ATHEROGENICS, INC. (US) 2001-09-27 WO disclosed
CN-1091288-A The oxytocin antagonist OTSUKA PHARMA CO LTD (JP) 1994-08-31 CN disclosed